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Nuclear retinoic acid receptors (RARs) are transcriptional regulators controlling the expression of specific
subsets of genes in a ligand-dependent manner.The basic mechanism for switching on transcription of
cognate target genes involves RAR binding at specific response elements and a network of interactions with
coregulatory protein complexes, the assembly of which is directed by the C-terminal ligand-binding domain
of RARs. In addition to this scenario, new roles for the N-terminal domain and the ubiquitin-proteasome system
recently emerged. Moreover, the functions of RARs are not limited to the regulation of cognate target genes,
as they can transrepress other gene pathways. Finally, RARs are also involved in nongenomic biological
activities such as the activation of translation and of kinase cascades. Here we will review these mechanisms,
focusing on how kinase signaling and the proteasome pathway cooperate to influence the dynamics of RAR
transcriptional activity.
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Introduction
Nuclear retinoic acid (RA) receptors (RARs) consist of
three subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3)
encoded by separate genes [Germain et al., 2006a;
Germain et al., 2006c], which function as
ligand-dependent transcriptional regulators
heterodimerized with retinoid X receptors (RXRs). For
each subtype, there are at least 2 isoforms, which are
generated by differential promoter usage and alternative
splicing and differ only in their N-terminal regions.
Activation of RARs by cognate ligands triggers
transcriptional events leading to the activation or
repression of subsets of target genes involved in cellular
differentiation, proliferation and apoptosis ([Bour et al.,
2006], and references therein).
The compounds that bind RARs and modulate their
activity are referred to as retinoids.This generic term
covers molecules that include natural vitamin A (retinol)
metabolites and active synthetic analogs. Retinoids are
hydrophobic, lipid-soluble, and of small size, so that they
can easily cross the lipid bi-layer of cell membranes.
Natural retinoids, exemplified by all-trans RA, are
produced in vivo from the oxidation of vitamin A
[Chambon, 2005; Sporn et al., 1994] (Figure 1). An
isomerization product of RA, 9-cis RA, also binds RARs
with high affinity, but whether this compound is a natural
bioactive retinoid remains controversial [Germain et al.,
2006b].
Beyond the natural compounds, major research efforts
in retinoid chemistry have been directed towards the
identification of potent synthetic molecules and led to the
generation of several classes of compounds with a panel
of activities ranging from agonists to antagonists, selective
or not to RAR subtypes [de Lera et al., 2007] (Figure 1).
Note that for (B) and (D) in Figure 1, a given ligand may
be considered as selective for a certain RAR subtype
when it exhibits an affinity difference greater than 100-fold
between its primary target and other receptors (see the
recommended usage of terms in the field of nuclear
receptors [Germain et al., 2006c]).
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selectivity of main retinoids. See text for details.
RARs have a well-defined domain organization and
structure, consisting mainly of a central DNA-binding
domain (DBD) linked to a C-terminal ligand-binding
domain (LBD). In the past 20 years, it has been
established that the basic mechanism for transcriptional
regulation by RARs relies on DNA binding to specific
sequence elements located in the promoters of target
genes and on ligand-induced conformational changes in
the LBD that direct the dissociation/association of several
coregulator complexes [Chambon, 1996; Germain et al.,
2003; Laudet and Gronemeyer, 2001; Lefebvre et al.,
2005].The description of the crystallographic structures
of these domains and the characterization of the
multiprotein complexes that specify the transcriptional
activity of RARs provided a wealth of information on how
these receptors regulate transcription. However, recent
years have witnessed the importance of the
ubiquitin-proteasome system and that of the N-terminal
domain (NTD), which also interacts with specific
coregulators, despite its native disordered structure [Bour
et al., 2007]. Moreover, according to recent studies, RARs
are involved in other nongenomic biological activities such
as the activation of translation and of kinase cascades.
These kinases target RARs and their coregulators, adding
more complexity to the understanding of RAR-mediated
transcription. In this review we will focus, in addition to
the basic scenario (DNA and ligand binding, dynamics of
coregulator exchanges at the LBD), on recent advances
in the nongenomic effects of RA, and on how
phosphorylation cascades, the NTD and the
ubiquitin-proteasome system cooperate for fine-tuning
RAR activity.
Structure/function analysis
As with most nuclear receptors, RARs exhibit a modular
structure composed of 6 regions of homology (designated
A to F, from the N-terminal to the C-terminal end) (Figure
2) harboring specific functions [Chambon, 1996; Laudet
and Gronemeyer, 2001]. Regions C and E, which
encompass the DBD and the LBD, respectively, are the
most conserved and important domains and govern the
classical model of RAR transcriptional activity. In contrast,
the A/B, D, and F regions are poorly conserved.
The DNA binding domain (DBD)
The DBD, which confers sequence-specific DNA
recognition, is composed of two zinc-nucleated modules,
two α-helices and a COOH-terminal extension (CTE)
[Zechel et al., 1994a; Zechel et al., 1994b]. Helix 1 and
helix 2 cross at right angles to form the core of the DBD
folding into a single globular domain that has been
determined by nuclear magnetic resonance and
crystallographic studies [Lee et al., 1993].The DBD
includes several highly-conserved sequence elements,
referred to as P, D, T and A boxes, that have been shown
to define or contribute to the response element’s
specificity, to a dimerization interface within the DBDs
and to contacts with the DNA backbone and residues
flanking the DNA core recognition sequence [Germain et
al., 2003; Germain et al., 2006c].
RARs bind as asymmetrically-oriented heterodimers with
RXRs, to specific DNA sequences or RA response
elements (RAREs), composed typically of two direct
repeats of a core hexameric motif, PuG (G/T) TCA
[Germain et al., 2003; Leid et al., 1992; Mangelsdorf and
Evans, 1995] and located in the regulatory sequences of
target genes.The classical RARE is a 5bp-spaced direct
repeat (referred to as DR5). However, the heterodimers
also bind to direct repeats separated by 1bp (DR1) or
2bp (DR2). Note that RXR homodimers also bind to DR1.
RAREs have been identified in the promoters of a large
number of RA target genes implicated in a wide variety
of functions. For instance, the classical DR5 elements
are found in the promoters of the RARβ2 gene itself [de
The et al., 1990], of the CYP26A1 (cytochrome 450, family
26, subfamily a, polypeptide 1) gene [Loudig et al., 2000]
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Review RARs and gene expressionFigure 2.  Schematic representation of the RAR proteins with the functional domains and the main phosphorylation sites. RARs have a
modular structure composed of six conserved regions designated A to F.The C region contains the DBD.The E region contains several domains, the
LBD, the AF-2 domain, the cyclin H binding domain and the dimerisation domain. It also contains a phosphorylation site for several kinases (PKA and
MSK1).The N-terminal domain (NTD) corresponds to regions A and B and contains a proline-rich motif with phosphorylation sites for Cdks and MAPKs.
and of several Homeobox (Hox) and hepatocyte nuclear
factor (HNF) genes [Dupe et al., 1997; Qian et al., 2000].
DR2 elements were identified in the CRBPI (Cellular
retinol binding protein I) and CRABPII (Cellular retinoic
acid binding protein II) gene promoters [Durand et al.,
1992; Smith et al., 1991].The only natural DR1 element
has been found in the rat CRBPII gene promoter
[Mangelsdorf et al., 1991].
On DR2 and DR5 elements, in vitro, RXR occupies the
5’ hexameric motif, whereas the RAR partner occupies
the 3’ motif (5’-RXR-RAR-3’) [Chambon, 1996; Laudet
and Gronemeyer, 2001]. In contrast, on DR1 elements,
the polarity is reversed, with the RAR DBD binding
upstream and the RXR DBD downstream
(5’-RAR-RXR-3’), switching the activity of the heterodimer
from an activator to a repressor of target genes in the
presence of RA.
So far, it has proved difficult to visualize the full-length
RXR-RAR heterodimer in complex with DNA. However,
the crystal structure of the DBDs in complex with DNA
has been solved [Khorasanizadeh and Rastinejad, 2001;
Rastinejad, 2001; Rastinejad et al., 2000]. Each DBD
interacts with the DNA major groove at the level of a
half-site through the P box of the first helix containing
three exposed residues responsible for discrimination
between different half-sites’ sequences.Then, they
arrange head-to-tail, with cooperative contacts between
the DBDs, leading to a mutual reinforcement of
protein-protein and protein-DNA interactions. Depending
on the DR spacing, different regions of the DBD of each
receptor are used to create the dimerization interface, in
order to achieve the required binding to the response
elements.The heterodimeric DBD interface that is
responsible for the binding of RXR-RAR heterodimers to
DR5 elements involves the D box of the RXR second
zinc-finger, and the tip of the RAR first zinc finger.
However, when the heterodimers bind with reverse
polarity to DR1 elements, they associate through the
second zinc finger of RAR and the so-called T box (within
the CTE- of RXR).This implies that the DBDs must be
rotationally flexible with respect to the LBD dimerization
interface and that the DNA curvature is different (for
review, see [Renaud and Moras, 2000] and references
therein). In conclusion, the DBDs of each
heterodimerization partner dictate the specificity of RARE
recognition and contribute through their dimerization to
increase DNA binding efficiency.
The ligand binding domain (LBD)
The structures of the RAR LBDs are rather similar, as
demonstrated by crystallographic studies [Moras and
Gronemeyer, 1998; Renaud and Moras, 2000;Wurtz et
al., 1996].The LBD is formed by 12 conserved α helices
and a β-turn (situated between H5 and H6). Helices 1-11
are folded into a three-layered, and parallel helical
sandwich with H4, H5, H8, H9 and H11 sandwiched
between H1, H2 and H3 on one side and H6, H7 and H10
on the other. In contrast, the C-terminal helix, H12, is
more flexible and adopts conformations that may differ
from one RAR subtype to the other (see below).The LBD
is functionally complex, as it contains the ligand-binding
pocket (LBP), the main dimerization domain and the
ligand-dependent activation function-2 (AF-2).
The ligand-binding pocket (LBP).The ligand-binding
pocket (LBP) comprises hydrophobic residues mainly
from helices H3, H5, H11 and the β-sheet, and
crystallographic studies revealed the structural basis of
ligand recognition [Bourguet et al., 2000a; Li et al., 2003;
Renaud et al., 1995].The shape of the LBP matches the
volume of the ligand, maximizing the hydrophobic
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binding [Gehin et al., 1999; Klaholz et al., 2000; Klaholz
et al., 1998].
Given that the precise contacts with ligands involve three
divergent residues located in H3, H5 and H11, which are
unique for each subtype receptor-cognate ligand pair, it
has been possible to generate subtype-selective ligands
[Germain et al., 2004] (Figure 1). For instance, the unique
polar residues S232 and M272 located in the LBP of
RARα and RARγ, respectively, have been exploited to
develop ligands that are specific for RARα (Am580) or
RARγ (BMS270394 or CD666).Via their amino group,
such ligands establish hydrogen bonds with RARα S232
or RARγ M272, thereby increasing affinity and selectivity
for RARα and RARγ, respectively. However, as the RARβ
LBP does not contain specific polar residues, the
development of RARβ-selective ligands is more
challenging [Germain et al., 2004]. Nevertheless, due to
differences in the volume and the shape of the LBPs of
each RAR subtype, it has been possible to generate
molecules with complex activities such as ligands that
are RARβ agonists and RARα/RARγ antagonists, the
larger size of RARβ LBP accounting for this mixed profile
[Chen et al., 1995; Germain et al., 2004].
The heterodimerization surface.The heterodimerization
surface involves residues from helices H7, H9, H10 and
H11, as well as loops L8-9 and L9-10 [Bourguet et al.,
2000b; Pogenberg et al., 2005]. Helices H9 and H10
contribute to more than 75% of the total dimerization
surface and constitute the core of the dimer interface. It
has been proposed that in RXR-RAR heterodimers, ligand
binding affects the stability and propagation of signals
across the heterodimerization surface, indicating that the
LBP and the dimerization interface are in some way
energetically linked [Brelivet et al., 2004].
The C-terminal helix 12, named AF-2.The C-terminal
helix 12, named AF-2, controls the ability of RARs to
interact with coregulators.The analysis of the crystal
structures of the unliganded and ligand-bound LBDs of
RXRα and RARα, respectively [Bourguet et al., 1995;
Renaud et al., 1995], highlighted the crucial
conformational flexibility of H12 and suggested a
mechanism by which AF-2 becomes transcriptionally
competent [Egea et al., 2001; Steinmetz et al., 2001].
Upon ligand binding, a series of intra-molecular
interactions cause the repositioning of H11 in the
continuity of H10 and the concomitant swinging of H12
which moves in a mouse trap model, sealing the “lid” of
the LBP and being tightly packed against H3 and H4.
Consequently, ligand binding is stabilized, and a new
hydrophobic cleft is formed between H3, H4 and H12 that
generates a defined interaction surface for transcriptional
coactivators. In contrast, in the case of the RARβ and
RARγ subtypes [Farboud et al., 2003; Farboud and
Privalsky, 2004; Hauksdottir et al., 2003], biochemical
studies proposed that, even in the absence of ligand, H12
would interact with H3 and adopt a constitutively closed
conformation that approximates the conformation of
liganded RARα.The importance of H12 in regulating
coactivator and corepressor binding is detailed below.
The N-terminal AF-1 domain (NTD)
Early studies revealed the importance of the NTD of
RARs, which corresponds to the A and B regions and
includes the activation function AF-1, in the control of
transcription of RA target genes [Nagpal et al., 1993;
Nagpal et al., 1992]. However, they did not elucidate the
underlying mechanism. It is interesting to note that within
the NTD, the A region differs between the different
subtypes and between isoforms [Chambon, 1996]. In
contrast, the B region is rather conserved and depicts a
proline-rich motif, which contains phosphorylation sites
(Figure 2). Most importantly, proline-rich motifs can bind
proteins with SH3 (Src-homology-3) or WW
(tryptophan-tryptophan) domains, with phosphorylation
preventing or favoring the interaction [Ball et al., 2005].
In contrast to the DBD and the LBD, there are still no
high-resolution structures available for the NTD of RARs.
Several biochemical and structural studies coupled to
structure prediction algorithms suggested that the NTDs
of RARs, as well as any member of the nuclear receptor
family, are of naturally-disordered structure [Lavery and
McEwan, 2005;Warnmark et al., 2003]. Most importantly,
it has recently emerged that unstructured proteins or
domains may be functional, undergoing transitions to
more ordered states or folding into stable secondary or
tertiary structures upon binding to DNA response
elements or to coregulatory proteins [Dyson and Wright,
2005; Liu et al., 2006]. Moreover, disordered domains
provide the flexibility that is needed for modification by
enzymes such as kinases and ubiquitin-ligases [Dyson
and Wright, 2005]. Such modifications may induce
changes in the structural properties of the domain with
profound impacts on its interactions with coregulators
and/or on the dynamics of adjacent structural domains.
The D region
Poorly conserved, this region is considered to serve as
a hinge between the DBD and the LBD, allowing rotation
of the DBD.Therefore, it might allow the DBD and the
LBD to adopt different conformations without creating
steric hindrance problems. It also harbors nuclear
localization signals.
The F region
This region extends C-terminal to helix 12 in RARs, but
is absent in RXRs. It is highly variable in length and
sequence among the different RAR subtypes and its
three-dimensional structure is still unknown. Interestingly,
region F is phosphorylated at multiple positions that might
modify the properties of RARs [Bastien et al., 2000;
Rochette-Egly et al., 1997].Though the functions of region
F are still poorly understood, it has been suggested that,
in the absence of ligand, this region would stabilize H12
of the RARα subtype in an unclosed conformation,
thereby enhancing corepressor binding [Farboud and
Privalsky, 2004]. According to recent studies, this region
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[Poon and Chen, 2008].
The canonical RAR-mediated regulation
of transcription with the LBD as the
main actor
RARs are considered to be highly-regulated DNA-binding
transcription factors that control transcription via several
distinct mechanisms, including both repression and
activation. Many years ago, it was established that after
site-specific DNA binding, the final transcriptional activity
of RARs depends on a set of associated proteins, the
so-called corepressors and coactivators. From a
molecular point of view, the discrimination between
corepressors and coactivators is governed by the position
of H12, which is directed by the ligand and contributes in
a critical manner to the generation or removal of
interaction surfaces.
The position of helix 12 governs the exposure
of interaction surfaces for corepressors or
coactivators
A recurring structural feature of corepressors and
coactivators is the presence of highly-conserved motifs
that are implicated in their recruitment at the LBD of
RARs.The nuclear receptor corepressor
(NCoR/NCoR1/RIP13) and silencing mediator for retinoid
and thyroid hormone receptors (SMRT/NCoR2/TRAC)
[Aranda and Pascual, 2001; Glass and Rosenfeld, 2000;
Privalsky, 2004] contain in their C-terminal part two and
three nuclear receptor interaction domains, respectively,
with an LxxI/HIxxxI/L motif, which forms an extended α
helix. Coactivators, which include essentially the p160
subfamily of steroid receptor coactivators (SRC), namely
SRC-1 (also referred to as NCoA-1), SRC-2 (TIF-2,
GRIP-1) and SRC-3 (pCIP, ACTR, AlB1, TRAM1, RAC3)
[Glass and Rosenfeld, 2000; Lefebvre et al., 2005; Perissi
et al., 1999], depict three copies of a highly-conserved
LxxLL motif, which forms a short α helix.
In the absence of ligand, the surface of the RARα LBD
presents a hydrophobic groove generated by H3, L3-4
and H4. It is worth noting that this surface is topologically
related to that involved in coactivator interaction, but
without H12 [Hu and Lazar, 1999] it can bind the extended
LxxI/HIxxxI/L motif of corepressors.The N-terminal part
of this motif extends in such a way that it masks the H12
interaction interface, thus explaining why the binding of
corepressors and coactivators is mutually exclusive.
Interestingly, the RARγ and RARβ subtypes interact poorly
with corepressors [Farboud et al., 2003; Hauksdottir et
al., 2003; Privalsky, 2004]. It has been proposed that
hydrophobic interactions between H3 and H12 sequester
H12 in a closed conformation, even in the absence of
ligand, thus occluding the corepressor-docking site. Note
that this closed conformation also prevents coactivator
binding.
Upon ligand binding, RARα undergoes conformational
changes and H12 becomes reoriented with a conserved
glutamate residue forming a charge clamp with a lysine
in H3. Such a charge clamp can specifically grip the ends
of a helix of the specific length specified by the LxxLL
motif of the coactivators, therefore allowing the leucine
side chains to pack into the hydrophobic cavity. Because
this ligand-activated charge clamp does not fit with the
extended LxxI/HIxxxI/L motif of corepressors, it has been
proposed that the alternative interactions of RARα with
corepressors and coactivators originate from the
difference in length of the interacting motifs that can be
accommodated in the hydrophobic cleft in the two
conformations [Germain et al., 2006c; Perissi et al., 1999].
Several crystal structures of RAR LBDs bound to synthetic
retinoids revealed that ligand interactions with H11 and
H12, or residues in their proximity, are primary
determinants of helix 12 position, and that H12 can adopt
not only the active and inactive positions, but also several
intermediary positions.This implies that relatively subtle
ligand modifications could significantly alter the
conformation of the LBD and the H12 molecular switch,
thereby generating distinct coregulator binding interfaces.
Therefore, a panel of compounds comprising not only
agonists, but also antagonists, inverse agonists and
partial agonists, selective or not for RAR subtypes, have
been generated [Altucci et al., 2007; de Lera et al., 2007;
Vivat-Hannah and Zusi, 2005] (Figure 1).
From a structural point of view, agonists induce the
repositioning of helix 12 and contribute in a critical manner
to the surface recognized by the LxxLL boxes of
coactivators. In contrast, antagonists which present a
bulky side-chain that cannot be accommodated within
the agonist binding cavity, prevent RARs from adopting
this conformation. Antagonists include pure AF-2
antagonists, exemplified by BMS195614, a selective
RARα antagonist (Figure 1).The crystal structure of the
BMS195614-bound RARα LBD complex revealed that
H12 packs on the groove formed by the carboxy terminal
part of H3, Loop L3-4 and H4 [Bourguet et al., 2000a],
which corresponds to the binding site for the coactivator
LxxLL motif.Therefore, one can reason that BMS195614
may prevent interaction of coactivators. As the
coactivator’s binding site overlaps with that for
corepressors, BMS195614 may also impede the
interaction of NCoR and SMRT corepressors.
In contrast, other antagonists, referred to as inverse
agonists and exemplified by AGN193109 or BMS204493
(Figure 1), are highly effective at inducing corepressor
interaction and thereby enhance silencing [Germain et
al., 2009; Germain et al., 2002; Klein et al., 1996; Sanglier
et al., 2004]. Although the molecular basis of inverse
agonism has not been elucidated yet, H12 of RAR LBD
bound to an inverse agonist should adopt an alternative
position, which does not occlude the hydrophobic groove
formed by H3 and H4.
Finally, AF-2 partial agonists-antagonists have been
identified [Chen et al., 1995; Germain et al., 2004; Klein
et al., 1996].The interest in such compounds, which
exhibit reduced efficacy compared to full agonists, is that
they can act in a cell type-selective manner and/or
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functions.
Transcriptional repression in the absence of
ligand
When genes are silent, DNA is packaged into a
highly-organized and compact nucleoprotein structure
known as heterochromatin, which limits the access of
promoter sequences to the transcriptional machinery and
therefore impedes all the transcriptional steps [Richards
and Elgin, 2002].The basic unit of chromatin is the
nucleosome, which consists of DNA wrapped around a
protein core containing two copies each of four histone
proteins. Protruding from the nucleosomes are the
N-terminal “tails” of the core histones, whose interaction
with DNA can be modulated upon covalent modifications
(acetylation, phosphorylation, methylation, ubiquitination,
etc.) [Narlikar et al., 2002].
According to the current model of gene regulation by
RARs [Dilworth and Chambon, 2001], in a context of
chromatin where the nucleosomes do not impede binding
to RAREs, the RARα subtype is a strong repressor of
target gene expression in the absence of ligand.This
repressive activity reflects the ability of RARα to bind
corepressors such as NCoR or SMRT (see above), which
do not harbor intrinsic enzymatic activities, but reside in
or recruit high molecular weight complexes endowed with
histone deacetylase activity (HDACs). Such complexes
have a well-characterized role in transcriptional repression
by deacetylating lysine residues in the N-terminal tails of
histones and generating a condensed chromatin structure
over the target promoter.The corepressor complexes
also contain other components such as TBL1 (Transducin
β-like 1) and TBLR1 (TBL1-related protein 1), which serve
as adaptors regulating corepressor assembly and function
[Perissi et al., 2004].
It is worth noting that according to recent studies, in the
absence of RA, RAR target genes have also been shown
to interact with other kinds of repressors such as
Topoisomerase IIβ [McNamara et al., 2008], Polycomb
group proteins (PcG) [Gillespie and Gudas, 2007a;
Gillespie and Gudas, 2007b] or calmodulin kinase IIγ
(CaMKIIγ) [Si et al., 2007], which also dissociate in
response to RA. PcG proteins act in large multimeric
complexes that mediate gene silencing, while CaMKIIγ
phosphorylates RARs, thereby enhancing their interaction
with corepressors.
Transcriptional activation upon ligand binding:
coregulator exchange at the LBD
To activate gene expression, RXR-RARα heterodimers
bound at DR5 elements will have to contend with the
repressive chromatin structures in order to allow the
recruitment of the transcriptional machinery.Today, it is
widely accepted that upon binding of a RARα agonist,
bound corepressors are released and RXR-RARα
heterodimers interact with coactivators of the p160 family
(see above) that upon association with larger complexes
with chromatin modifying and remodeling activities will
decompact repressive chromatin.
Interestingly, an RXR agonist cannot activate RXR-RARα
heterodimers unless the RARα partner is liganded first.
Several models have been proposed to account for this
phenomenon referred to as “subordination” or “silencing”
(for review see [Greschik and Moras, 2003] and
references therein), but most of them require more crystal
structures for validation. Importantly, one model proposed
that liganded RXR cannot dissociate corepressors from
the RARα partner [Germain et al., 2002] and that the
binding of agonists to RARα is essential for corepressor
dissociation. In agreement with this idea, the RXR-RARβ
heterodimer, in which RARβ only weakly recruits
corepressors, responds better to a RXR agonist [Germain
et al., 2002]. Finally, in the presence of both RAR and
RXR agonists, there is synergy originating from the RAR
agonist-induced dissociation of corepressors and the
subsequent cooperative binding of coactivators to the
two partners.
The p160 coactivators serve as adaptors recruiting other
complexes with different enzymatic activities [Glass and
Rosenfeld, 2000; Lefebvre et al., 2005; McKenna and
O'Malley, 2002; Rosenfeld et al., 2006; Zhao et al., 2008]:
(i) histone acetyltransferases (HATs) such as CBP/p300
(CREB binding protein) and p/CAF (p300/CBP-associated
factor) (ii) histone methyl transferases (HMTs) such as
CARM1 (coactivator-associated arginine
methyltransferase 1) or PRMT1 (protein arginine methyl
transferase 1), (iii) ubiquitinases/deubiquitinases and (iv)
nucleosome remodeling complexes such as SWI/SNF
(switch/sucrose non-fermenting). All these complexes
alter the chromatin structure surrounding the promoter of
target genes and create tags or binding sites that form a
“histone code” read by particular effectors, which in turn
mediate distinct outcomes [Sims and Reinberg, 2008]. In
some examples, these chromatin marks function in a
combinatorial manner.This code coordinates the
recruitment of additional HATs or HMTs for further
chromatin decompaction. It also orchestrates the
recruitment of chromatin remodelers, which use the
energy of ATP-hydrolysis to reposition nucleosomes
through sliding them in cis or displacing them in trans,
allowing the formation of nucleosome-free or
nucleosome-spaced regions at the promoter [Narlikar et
al., 2002]. It has also been proposed that activated RARs
recruit the transcriptional machinery, including the
multisubunit Mediator complex, RNA polymerase II and
the general transcription factors [Bastien and
Rochette-Egly, 2004; Dilworth and Chambon, 2001;
Rochette-Egly, 2005; Rosenfeld et al., 2006].This step
would require the association of RARs with a specific
subunit of the Mediator complex, which was identified as
DRIP205/TRAP220, and which contains two LxxLL motifs
[Lefebvre et al., 2005].
It must be noted that, in vivo, RARs appear to employ
different programs for gene activation, depending on the
target gene promoter context. Indeed, recent chromatin
immunoprecipitation experiments demonstrated that in
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occupy with RARα the promoters of some endogenous
genes, even in the absence of RA [Flajollet et al., 2006;
Pavri et al., 2005; Perissi et al., 2004]. In that context,
transcription initiation and the recruitment of the general
transcription factors such as TFIIH at the promoter have
been shown to depend on the dissociation from the
Mediator complex, of the inhibitory cyclin-dependent
kinase 8 (cdk8) subunit [Andrau et al., 2006; Elmlund et
al., 2006]. In addition, recent studies from our laboratory
revealed that in the absence of ligand, not all RA target
promoters are occupied by RARs and that several events
have to be initiated and coordinated to make the response
elements available for RAR recruitment (see below and
[Bruck et al., 2009]). Interestingly, in the context of
promoters with RAREs that are distant from the
transcription start site, RARs in association with
coregulators and RNA PolII initiate the formation of DNA
loops [Bruck et al., 2009].
Role of other unconventional coregulators
The model involving coactivators that positively modulate
transcription has been challenged by the identification of
three other unconventional coregulators, the receptor
interacting protein of 140kDa (RIP140/NRIP1) [Augereau
et al., 2006; Hu et al., 2004], the preferentially expressed
antigen in melanoma (PRAME) [Epping et al., 2005] and
the transcription intermediary factor-1 α (TIF1α/Trim24)
[Le Douarin et al., 1995], which repress transcription
despite their ligand-dependent recruitment to RARs via
LxxLL motifs (one in TIF1α, seven in PRAME and nine
plus a modified LxxML motif in RIP140) [Farooqui et al.,
2003; Heery et al., 1997]. In fact, these coregulators
would constitute a functional negative feedback
mechanism limiting and/or ending RAR activity.The
mechanism of TIF1α-mediated repression has not been
elucidated yet [Khetchoumian et al., 2007]. However, the
repressive activity of RIP140 has been attributed to the
presence of four autonomous repressive domains, one
of them recruiting HDACs [Wei et al., 2000], and that of
PRAME to the recruitment of PcG proteins [Epping et al.,
2005].
A plethora of other coregulator molecules for RA-bound
RARs has been identified. Among these, are coactivators
devoid of LxxLL motifs such as the thyroid receptor
interacting protein-1 (TRIP1/SUG-1) [vom Baur et al.,
1996], which is a subunit of the 19S regulatory
subcomplex of the proteasome with an ATPase activity
and which contributes to the transcription of RAR target
genes [Ferry et al., 2009].There are also coregulators
that interact with domains other than the coactivators
hydrophobic cleft formed between H3, H4 and H12. As
such, cyclin H interacts with L8-9 and the beginning of
H9 [Bour et al., 2005a], allowing the recruitment of TFIIH
(see below).There is also CRABPII, which in association
with cyclin D3 [Delva et al., 1999; Despouy et al., 2003],
serves as a RA-channeling molecule to the receptor
[Budhu and Noy, 2002; Dong et al., 1999]. Interestingly,
upon deregulation of CRABPII expression, RA is shuttled
to peroxisome proliferator-activated receptors (PPARβ/δ)
rather than to RARs, by another intracellular lipid-binding
protein, generating RA resistance [Schug et al., 2008].
New unconventional nongenomic
effects of RARs: kinase activation and
translation induction
Activation of the MAPK pathways
A new concept, which has recently developed is that, in
addition to its well-established nuclear function to regulate
gene expression, RA rapidly activates mitogen-activated
protein kinases (MAPKs). Indeed, recent studies indicated
that RA activates p38MAPK in several cell lines such as
fibroblasts, mouse embryocarcinoma cells, mammary
breast tumor cells and leukemia cells [Alsayed et al.,
2001; Bruck et al., 2009; Gianni et al., 2002a; Gianni et
al., 2006]. Subsequently, p38MAPK activates a
downstream mitogen and stress-activated kinase, MSK1
[Bruck et al., 2009]. However, in neuronal cells
(neuroblastoma cells, hippocampus neurons and P19
cells) and Sertoli cells, RA instead rapidly activates
p42/44 MAPKs [Chen and Napoli, 2008; Gupta et al.,
2008; Masia et al., 2007; Zanotto-Filho et al., 2008].
MAPK activation occurs very rapidly (within minutes after
RA addition) subsequent to the prior activation of
upstream kinases such as phosphoinositide 3-kinase
(PI3K) [Bastien et al., 2006; Masia et al., 2007; Pan et
al., 2005], RAC-1 [Alsayed et al., 2001] or protein kinase
C δ (PKCδ) [del Rincon et al., 2004; Kambhampati et al.,
2003].This suggests an atypical, nongenomic activation
event similar to that described for steroid receptors. In
line with this new concept, though classically thought to
reside in the nucleus, RARs have been recently reported
to be present in the cytosol or in membranes, in
association with PI3K or Src kinases [Dey et al., 2007;
Masia et al., 2007]. Such observations strongly suggest
a new paradigm by which RARs would integrate
membrane/cytoplasm events that would orchestrate
several post- t reductional modifications in order to
fine-tune transcription (Figure 3 and Figure 4).
RNA binding and translation control
Very recent studies suggested another new nongenomic
role of RARα as a RNA-binding protein.Two laboratories
independently demonstrated that RA activates dendrite
protein synthesis via a process that requires RARα (and
not the other RAR subtypes) and is independent of
transcriptional regulation [Chen and Napoli, 2008;
Maghsoodi et al., 2008]. Indeed, they found that RARα
is exported to neuronal dendrites, where it is associated
with a subset of mRNAs such as the glutamate receptor
1 (GluR1) mRNA [Chen et al., 2008].This binding, which
is mediated by the C-terminal F region of RARα, directly
represses the translation of these mRNA [Poon and Chen,
2008]. Interestingly, RA binding to RARα reduces its
association with GluR1 mRNA and relieves translational
repression. Such effects have been correlated to synaptic
function and plasticity [Aoto et al., 2008]. As RA also
activates MAPKs in neuronal cells [Chen and Napoli,
2008] and as the F region can be phosphorylated
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Review RARs and gene expressionFigure 3.  Crosstalk between kinase cascades and genomic pathways induced by RA. In response to RA, PKCδ, p38MAPK and the downstream
protein kinase MSK1 are activated through rapid nongenomic effects that occur in the cytosol or at the membrane. MSK1 phosphorylates RARα at
S369 located in the LBD, subsequently allowing the docking of cyclin H within TFIIH and the formation of a RARα/TFIIH complex.Then the cdk7 subunit
of TFIIH phosphorylates the NTD of RARα at S77. Finally, RARα phosphorylated and associated with TFIIH is recruited to response elements located
in the promoter of target genes. P38MAPK, MSK1 and PKCδ also phosphorylate corepressors, coactivators and histones. All these phosphorylation
processes cooperate to coordinate and fine-tune the dynamic exchanges between RARs, coactivators, corepressors and the promoters of target genes
Figure 4.  Recapitulation of the different signaling pathways involved in RAR phosphorylation. The pathways that are induced by RA are in
red.The consequences (positive or negative) of RAR phosphorylation on RA target genes transcription are also indicated. (1) Gianni et al., 2002a. (2)
Bour et al., 2005b. (3) Sun et al., 2007. (4) Delmotte et al., 1999. (5) Srinivas et al., 2005. (6) Bruck et al., 2009. (7) Rochette-Egly et al., 1997. (8) Poon
and Chen, 2008.
www.nursa.org  NRS  | 2009 |  Vol. 7 |  DOI: 10.1621/nrs.07005 | Page 8 of 18
Review RARs and gene expression[Rochette-Egly et al., 1997], further studies are required
to delineate the influence of the kinase signaling pathways
on translation [Chen and Napoli, 2008]. Overall, these
new nongenomic effects expand the scope of the biologic
functions of RARα beyond its role as a regulator of gene
transcription.
Crosstalk between kinase cascades and
genomic pathways induced by RARs
The RA-activated p38MAPK/MSK1 pathway leads
to a coordinated phosphorylation cascade
targeting RARα, their coregulators and histones
Recent studies from our laboratory demonstrated that
RARα becomes rapidly phosphorylated in response to
RA at two serine residues, one being located in the LBD
(serine 369) and the other one in the NTD (serine 77)
[Bruck et al., 2009] (Figure 2). Interestingly, serine 369
is an exposed residue located between helices 9 and 10
within the LBD. It belongs to an arginine-lysine-rich motif
that corresponds to a consensus phosphorylation motif
for several kinases including the cyclic AMP-dependent
protein kinase (PKA) and MSK1, suggesting that it might
integrate several signaling pathways [Bruck et al., 2009;
Gaillard et al., 2006]. In contrast, serine 77 located in the
NTD, belongs to a proline-rich motif.The kinase
responsible for phosphorylating this site has been
identified as cdk7 [Rochette-Egly et al., 1997], the activity
of which depends on its association with cyclin H and
MAT1 to form the ternary cyclin-dependent kinase
(CDK)-activating kinase (CAK) complex of TFIIH, a
general transcription factor composed of 10 subunits
[Giglia-Mari et al., 2004].The correct positioning of the
cdk7 kinase and thereby the efficiency of the NTD
phosphorylation by cdk7 rely on the docking of cyclin H
at a specific site of the LBD located in L8-9 and the
N-terminal part of H9 [Bour et al., 2005a; Gaillard et al.,
2006].To our knowledge, it was the first example of
cooperation between the N- and C-terminal domains of
RARs through a kinase complex.The docking site of
cyclin H is conserved between RARs, but not in other
nuclear receptors and other cdk7 targets, and differs from
the other cyclin docking sites.Therefore, it would elicit
the specificity of RAR phosphorylation by cdk7.
Recently, Bruck et al. demonstrated that the RA-induced
phosphorylation of RARα results from a coordinated
phosphorylation cascade starting with the phosphorylation
of serine 369 by MSK1 [Bruck et al., 2009]. As serine 369
is in close proximity to the docking site for cyclin H,
phosphorylation of this residue induces an allosteric
network, which promotes the binding of cyclin H [Gaillard
et al., 2006] and thereby of cdk7, with a characteristic
downstream consequence on the phosphorylation of the
NTD at serine 77.
The phosphorylated serine residues located in the LBD
and in the NTD are conserved between RARs.
Accordingly, the RARγ subtype is also phosphorylated at
the NTD (serine 79 in RARγ1 and serine 68 in RARγ2)
by the cdk7 subunit of TFIIH [Bastien and Rochette-Egly,
2004]. Interestingly, RARγ (but not RARα) is also
phosphorylated at an additional nearby serine residue
(serine 77 in RARγ1 and serine 66 in RARγ2) by
p38MAPK [Gianni et al., 2002a; Gianni et al., 2002b]
(Figure 2). However, whether RARγ can be
phosphorylated at the LBD site (serine 371 in RARγ1 and
serine 360 in RARγ2) [Rochette-Egly et al., 1995] by
MSK1 in response to RA remains to be demonstrated.
RA also activates p42/p44MAPK, but whether this kinase
is able to phosphorylate RARs has not been elucidated
yet. Note, however, that in neuronal cells, RA-activated
p42/p44MAPK phosphorylates other activators of
transcription, switching them into repressors of other gene
programs [Gupta et al., 2008], while in Sertoli cells, they
induce apoptosis [Zanotto-Filho et al., 2008].
Recently, the p160 SRC-3 coactivator [Gianni et al., 2006]
and TBLR1, a component of the corepressor complexes
[Perissi et al., 2008], have also been shown to be
phosphorylated in response to RA by p38MAPK and
PKCδ, respectively. Interestingly, the p160 family of
coactivators [Lopez et al., 2001; Rowan et al., 2000;Wu
et al., 2007;Wu et al., 2004;Yi et al., 2008], as well as
p300/CBP [Vo and Goodman, 2001], RIP140 [Gupta et
al., 2005; Huq et al., 2005] and SMRT [Jonas and
Privalsky, 2004], are also targets for MAPKs or other
kinases, but whether their phosphorylation occurs in
response to RA will require further investigations. Finally,
MSK1 was recently found to be recruited to RARα target
promoters in the active phosphorylated form, leading to
increased phosphorylation of serine 10 on histone H3
[Bruck et al., 2009].
RAR phosphorylation and the transcription of
RA target genes
Early studies demonstrated the importance of
TFIIH-mediated phosphorylation of RARs in the
transcription of RA target genes [Bastien et al., 2000;
Rochette-Egly et al., 1997].This has been corroborated
in studies using cells from patients suffering from
Xeroderma pigmentosum, which harbor mutations in a
TFIIH subunit [Keriel et al., 2002]. Such cells are
characterized by a hypophosphorylation of the RARα
subtype and a deficient RA response, but the underlying
mechanism was not elucidated.
The recent results by Bruck et al. [Bruck et al., 2009]
provided new information on how phosphorylation
influences the transcriptional activity of RARα. Indeed,
they demonstrated that the RA-induced phosphorylation
cascade initiated by MSK1 and ending with the
phosphorylation of the NTD by cdk7, promotes RARα
recruitment to target promoters. Such results corroborate
the importance of NTD phosphorylation in the
transcriptional activity of RARs. However, it raises the
question as to how phosphorylation of this unstructured
domain can actually regulate DNA binding. In contrast,
in the case of RARγ, the promoters are already occupied
by the receptor in the absence of ligand [Gillespie and
Gudas, 2007a; Gillespie and Gudas, 2007b] and RARγ
phosphorylation occurs at the promoters (our unpublished
results), suggesting that phosphorylation of the NTD might
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interactions [Lavery and McEwan, 2005;Warnmark et
al., 2003].
Phosphorylation of coactivators and corepressors that
occurs in response to RA is also crucial for RARα
transcriptional activity [Perissi et al., 2004; Rosenfeld et
al., 2006]. Analogous to steroid nuclear receptors [Dennis
and O'Malley B, 2005;Wu et al., 2005;Yi et al., 2005], it
has been suggested that SRC-3 phosphorylation [Gianni
et al., 2006] fine-tunes the dynamics of the exchanges of
the coactivator with RARα and/or other coregulators. In
contrast, phosphorylation of TBLR1 mediates
ubiquitination and degradation of NCoR/SMRT [Perissi
et al., 2008] and thereby overcomes
SMRT/NCoR-dependent repression.
Finally, MSK1-mediated phosphorylation of H3 contributes
to RARα target gene induction, probably as a chromatin
mark accounting, in cooperation with other histone
modifications, for the dissociation of repressive complexes
and/or the recruitment of chromatin-remodeling
complexes [Bruck et al., 2009;Vicent et al., 2006].
In conclusion, these recent findings challenged the
conventional view of stable RAR-based, template-bound
complexes and suggested a dynamic model with rapid,
and sequential series of exchanges between RARs and
coregulators at the promoter [Bour et al., 2007;
Rochette-Egly, 2005] (Figure 3). Such exchanges,
carefully coordinated by phosphorylations, would act as
a “transcriptional time clock”, so that at the end, the
correct proteins are present with the right activity, at the
right place and at the right time.
RAR phosphorylation and other
posttranslational modifications
According to recent studies, RARs are also targets for
other modifications such as ubiquitination and
methylation.Today, it is accepted that interplay between
different posttranslational modifications is an important
mechanism to achieve an integrated regulation of RAR
activity, suggesting that a protein code similar to that
proposed for histones could be applied to RARs [Sims
and Reinberg, 2008].The best example of crosstalk
between modifications is the phosphorylation-dependent
ubiquitination and subsequent proteasomal degradation
of the RARγ subtype [Gianni et al., 2002a; Kopf et al.,
2000]. Central to this phosphorylation function, was the
observation that RARγ with the serines located in the
NTD substituted with alanine residues exhibit reduced
ubiquitination and degradation by the 26S proteasome
upon cognate ligand binding.Whether phosphorylation
controls the recruitment of the ubiquitin-proteasome
machinery directly or indirectly through conformational
changes would require further investigations.
RARs can also be methylated. Accordingly, the group of
Li-Na Wei reported that RARα can be tri-methylated at a
lysine residue located in the LBD [Huq et al., 2007] and
mono-methylated at another lysine located in the DBD
[Huq et al., 2008]. In both cases, methylation plays a
positive role in RARα transcriptional activity, but the basal
molecular mechanisms, as well as the methylases
involved, remain to be characterized.Whether methylation
functions in a combinatorial manner with phosphorylation
also remains to be demonstrated. Finally, whether RARs,
as most nuclear receptors, can also be targeted by other
modifications such as acetylation or SUMOylation would
require further investigations.
RAR phosphorylation in response to other
cellular signaling pathways: abrogation of the
RA response
Today, new roles for phosphorylation in regulation of
RAR-mediated transcription are being discovered at an
accelerated pace and it is increasingly clear that RAR
phosphorylation can also occur in the absence of ligand.
Indeed, several exogenous signals such as growth
factors, insulin, stress or cytokines activate cytosolic
kinase cascade pathways, ending at Akt, PKC or c-Jun
N-terminal kinases (JNKs), which can enter the nucleus
and phosphorylate RARs at residues different from those
that are normally phosphorylated in response to RA
(Figure 4).While such phosphorylation processes usually
activate the transcriptional activity of steroid receptors
[Faus and Haendler, 2006; Moggs and Orphanides, 2001],
they instead inactivate RARα activity. As an example,
PKC can phosphorylate the DBD of RARs, resulting in
nuclear export [Sun et al., 2007] or in abrogation of RARs
heterodimerization and binding to DNA [Delmotte et al.,
1999]. Moreover, in cancers characterized by amplified
or deregulated JNK or Akt activities, due to amplification
of aberrant activity of receptor or cytoplasm tyrosine
kinases [Blume-Jensen and Hunter, 2001], several
residues located at the C-terminal end of RARα are
phosphorylated, contributing to RARα degradation
[Srinivas et al., 2005; Srinivas et al., 2006]. SMRT is also
phosphorylated by Akt [Lefebvre et al., 2006], with a
subsequent stabilization of the RAR-SMRT interaction.
The nongenomic effects of RARs on the p38MAPK/MSK1
pathway are also abrogated [Bruck et al., 2009]. Finally,
such cancers are RA-resistant [Neri et al., 2003;Tari et
al., 2002].
In conclusion, RAR transcriptional activity, which is
controlled by multiple players acting in a fine-tuned,
spatially- and temporally-coordinated manner, requires
the integrity of the signaling pathways.
New actors in RAR-mediated
transcription: the ubiquitin-proteasome
system and coregulators of the NTD
New roles for the ubiquitin-proteasome pathway,
with and without proteolysis
A new aspect is that, in response to RA, RARs [Gianni
et al., 2002a; Kopf et al., 2000; Zhu et al., 1999], as well
as their coactivators such as SRC-3 [Gianni et al., 2006],
are ubiquitinated and degraded by the 26S, which
consists of the 20S proteolytic core capped by the 19S
regulatory complex that recognizes the ubiquitinated
proteins and prepares them for entry into the 20S core
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of RARs depends on the RA-induced recruitment at the
AF-2 domain of the ubiquitin and/or degradation
machineries [Kopf et al., 2000]. In the particular case of
the RARγ subtype, degradation and ubiquitination of the
receptor depends on the prior phosphorylation of the NTD
[Gianni et al., 2002a; Kopf et al., 2000]. Degradation of
SRC-3 also depends on the phosphorylation of the
coactivator by p38MAPK [Gianni et al., 2006].
The exact role of the proteolytic activity of the proteasome
in RAR-mediated transcription is not yet clear [Bastien
and Rochette-Egly, 2004; Bour et al., 2007]. Since RAR
and SRC-3 degradation occurs rather late after RA
addition, when transcription has declined, a radical
hypothesis would be that as for most “activators” of
transcription, proteasomal degradation provides an
efficient way to limit RAR function and/or to signal the
end of the transcriptional process [Tansey, 2001].
However, according to the newly-arising concept that
dynamic exchanges of coregulators are required for
transcription to proceed, proteolysis might serve to clear
out corepressors and/or coactivators so that other
coregulators can subsequently bind [Collins and Tansey,
2006; Dennis and O'Malley B, 2005; Lipford and
Deshaies, 2003]. In line with this theme, two components
of the RAR coregulatory complexes, TBL1 and TBLR1,
have been shown to serve as specific adaptors for the
recruitment of the proteasome and the degradation of
corepressors, in order to mediate their exchange for
coactivators [Perissi et al., 2004; Perissi et al., 2008].
However, there is an increasing body of evidence that
the ubiquitin-proteasome system would also play a role
in the control of RA-mediated transcription without
proteolysis. In that context, it is worth noting that SUG-1,
one of the six ATPases of the 19S, interacts with RARs
[vom Baur et al., 1996] and SRC-3 [Ferry et al., 2009],
and as such, is recruited to the promoters of RA target
genes, thereby contributing to their transcription [Ferry
et al., 2009]. It has been proposed that the ATPase
subunits of the 19S regulatory subcomplex would unfold
or refold the components of the regulatory transcriptional
complexes, such as the SAGA
(spt-Ada-Gcn5-acetyl-transferase) complex [Lee et al.,
2005], in order to facilitate their loading and/or removal
at promoters.They would also reconfigure local chromatin
in order to promote recruitment of appropriate histone
modifiers [Ezhkova and Tansey, 2004].Thus, the
proteasome pathway would control the composition of
complexes at the promoters of RAR target genes and the
coordination of the different steps at the promoter,
consistent with the idea that transcription is a dynamic
process with continual exchange and turnover of
coregulators [Collins and Tansey, 2006; Muratani and
Tansey, 2003; Rochette-Egly, 2005].
A new role for the NTD of RARs via the binding
of proteins with WW or SH3 domains
The NTD phosphorylation site belongs to a proline-rich
motif (Figure 2). Most importantly, such motifs bind
proteins with SH3 or WW domains, with phosphorylation
preventing or favoring the interaction [Kay et al., 2000;
Macias et al., 2002; Sudol et al., 2001; Zarrinpar and Lim,
2000]. In line with this, the phosphorylated NTD of RARα
has been shown to bind the proline isomerase Pin1
(protein interacting with NIMA (never in mitosis A))
[Brondani et al., 2005; Gianni et al., 2009], a WW
domain-containing protein which induces cis-trans
isomerisation of the proline residues that follow the
phosphorylated serines in order to create new specific
recognition sites for interacting factors [Wulf et al., 2005].
A recent study performed in our laboratory has uncovered
an interaction between the unphosphorylated NTD of the
RARγ subtype and vinexin β [Bour et al., 2005b], which
is one of a growing number of actin-binding proteins that
are also present in the nucleus and modulate transcription
[Bour et al., 2007].Vinexin β is devoid of any enzymatic
activity and is an adaptor characterized by the presence
of three SH3 domains [Kioka et al., 2002], with the third
one, proximal to the C-terminus, being involved in the
interaction with the proline-rich motif of RARγ. As vinexin
β is a repressor of RARγ-mediated transcription, it has
been proposed that it would act as a scaffold between
RARγ and nuclear proteins that interact with its two other
SH3 domains [Mitsushima et al., 2006a; Mitsushima et
al., 2006b], potentially forming a trimeric complex that
maintains RARγ in an inactive state [Bour et al., 2007].
In support of this hypothesis, is the recent description of
a direct interaction between vinexin β and SAFB2
(scaffold attachment factor B2 protein), a novel nuclear
receptor corepressor [Townson et al., 2003]. Importantly,
the interaction with vinexin β occurs only when the cdk7
phosphorylation site within the proline-rich motif, is not
phosphorylated [Bour et al., 2005b] and vinexin β is
released in response to RA (Lalevée and Rochette-Egly,
unpublished results).The relative contribution of the
ligand and of the cdk7-mediated phosphorylation of the
NTD, in vinexin β dissociation, is a current matter of
investigation in our laboratory.
Recently, other coregulators such as Acinus-S’, a nuclear
protein implicated in apoptotic chromatin condensation
and mRNA processing, have been shown to interact with
the C-terminal part of the NTD, thereby repressing RAR
transcriptional activity [Vucetic et al., 2008]. However,
this interaction involves residues distinct from those of
the proline-rich motif, suggesting another mechanism of
action.
Transrepression by RARs (anti-AP1)
Evidence has accumulated over the past few years that
the action of RARs is not restricted to the regulation
(positive or negative) of cognate target gene expression,
but also concerns several other gene programs by
interfering with other nuclear receptors [Gupta et al., 2008]
or with transcription factor complexes such as activating
protein-1 (AP-1) (for review see [Germain et al., 2003;
Lefebvre et al., 2005]).The AP-1 complex regulates the
expression of several genes involved in oncogenic
transformation and cell proliferation. Its activity is
determined by the composition of the dimers, which
include members of the fos (c-fos, FosB, Fra-1 and Fra-2)
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controlled by a complex network of phosphorylations.The
inhibition of AP-1-driven transactivation by RARs is the
prototype of transrepression and has been revealed in
the context of several genes such as the collagenase and
stromelysin genes [Lafyatis et al., 1990; Lin et al., 2000;
Nicholson et al., 1990]. Generally, AP-1 inhibition is driven
by liganded RARs, though AP-1 has been found to be
inhibited in a ligand-independent manner by the RARβ
subtype [De-Castro Arce et al., 2007; De-Castro Arce et
al., 2004]. How RARs interfere with AP-1 activity and
through which domains, is complex, and several models
have been proposed ([Altucci and Gronemeyer, 2001;
Lefebvre et al., 2005] and references therein), such as
(i) a direct interaction with Jun/Fos family members, (ii)
disruption of Jun-Fos dimerization (iii) competition with
the recruitment of a common transcriptional coactivator
such as CBP, or (iv) inhibition of JNKs, thereby preventing
the phosphorylation-dependent activation of c-jun [Dedieu
and Lefebvre, 2006]. Despite these models, the molecular
basis of the anti-AP-1 activity of RARs has remained
elusive and debated [Benkoussa et al., 2002; Suzukawa
and Colburn, 2002].
In general, AP-1 inhibition correlates with the growth
inhibitory effect of retinoids on tumors [Karamouzis and
Papavassiliou, 2005].Therefore, the capacity of RARs
to inhibit AP-1-responsive genes seems to be the basis
for the chemo preventive and chemotherapeutic effects
of RA in the treatment of hyperproliferative diseases
[Altucci and Gronemeyer, 2001; Dong et al., 1994; Li et
al., 1996]. In this context, selective retinoids that
dissociate the inhibition of AP-1 activity from the classical
RARE-dependent activation of transcription have been
generated [Chen et al., 1995; Fanjul et al., 1994;
Resche-Rigon and Gronemeyer, 1998]. Such compounds
are promising therapeutic agents and provide valuable
tools to address the mechanism of the RAR/AP-1
crosstalk, the importance of which for growth control and
cancer is now established.
Conclusion
The well-established function of RARs is to regulate gene
expression in the nucleus. In this context, it is clear that
switching on RAR transcriptional activity relies on
conformational changes induced by ligand binding and
on dynamic series of exchanges with coregulatory
complexes. However, today there is mounting evidence
that RARs have a wider spectrum of biological activities,
through nonconventional, nongenomic mechanisms.
Indeed, in response to RA, RARs can activate translation,
as well as signaling pathways, independently of
transcriptional mechanisms. Further work is needed to
determine how RARs activate MAPKs and how RAR
phosphorylation at the NTD controls the
association/dissociation of specific partners with SH3 or
WW domains to modulate the transcription of RA target
genes. Up to now, only a few proteins have been shown
to interact with the NTD of RARs [Bour et al., 2005b;
Brondani et al., 2005;Vucetic et al., 2008] and further
studies are required to investigate whether the NTDs of
the different RAR subtypes can interact with other proteins
involved in processes such as mRNA processing and
splicing, or are endowed with chaperone or actin-binding
activities. As phosphorylation of the RARγ NTD marks
the receptor for ubiquitination and proteasomal
degradation, ubiquitin ligases might also be interesting
candidates. Ultimately, the challenge is to decipher at the
molecular level how coregulator exchanges at the NTD
cooperate with phosphorylations to modulate transcription.
Finally, given that aberrant retinoid signaling mechanisms
have been associated with several diseases [Keriel et
al., 2002] or cancers [Neri et al., 2003;Tari et al., 2002],
more work is required to understand the molecular
pathways that are controlled by RARs, notably those
underlying the antiproliferative and anticancer activities
of retinoids, with a particular effort on the role of
phosphorylation processes. Moreover, in line with the
improved use of retinoids in therapy, novel synthetic RAR
ligands harboring increased selective properties with little
toxicity compared with classical retinoids, will have to be
generated. Finally, combination of retinoids with agents
targeting kinases [Vitoux et al., 2007] or epigenetic
modifications such as HDAC inhibitors [Cras et al., 2007;
Egger et al., 2004; Feinberg and Tycko, 2004] are
increasingly being sought in order to improve the retinoid
response and/or to overcome retinoid resistance.
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